Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.
about
Checkpoint Inhibitors and Their Application in Breast CancerEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyA genome-wide systematic analysis reveals different and predictive proliferation expression signatures of cancerous vs. non-cancerous cellsMeta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancerTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.DACH1 suppresses breast cancer as a negative regulator of CD44.Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.Characterization of tumor-associated B-cell subsets in patients with colorectal cancer.Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancerGene-expression signature functional annotation of breast cancer tumours in function of agemiR-30e* is an independent subtype-specific prognostic marker in breast cancerInfluenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer.The influence of cancer tissue sampling on the identification of cancer characteristics.Conservation of immune gene signatures in solid tumors and prognostic implications.HEROD: a human ethnic and regional specific omics database.Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesisEnrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosisERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast CancerOncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.Maspin Gene Expression in Invasive Ductal Carcinoma of Breast.Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features.Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis.Can immunity to breast cancer eliminate residual micrometastases?BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcomeA 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?Breast cancer classification: linking molecular mechanisms to disease prognosis.Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?Advances in systemic therapy for metastatic breast cancer: future perspectives.A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes.Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments.Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors.KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approachIdentification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.
P2860
Q26745442-D2B49467-E49D-4701-BBEA-75B5E6FC0AB1Q28084489-E51FE24B-812E-4A51-BD37-1D6FA0FE0BC1Q28533665-385E33CA-FA58-45E1-9B51-25FC193E511FQ33555064-6330ADE9-A172-405F-9BED-144301255965Q33769821-748DC6F5-FCD9-4E89-9C7F-ECB1DA0D72D1Q33849252-78824303-6DE4-405F-8693-68E11EF46C96Q33916814-732AC45D-17A5-4960-8C48-E17A398D8C8DQ34103969-9ACD2EC6-543A-4E5A-9E6A-7F695865BC09Q34558758-D5887173-CF7E-4E81-9522-E09D40F2F071Q35091690-D3E63A1B-B863-4232-81A6-73EE8CDD88ECQ35227810-CA4491CC-2473-4C8B-A078-35D56A8B58C4Q35754593-23C72940-2C37-4B3B-A7A0-AD8864094E6BQ35849104-6FE369BF-B9B1-4732-92F8-B493B509CCE9Q35863168-AE01CDAC-370E-4BB0-9A1C-DC1525F6948DQ35887739-B5AABF57-BEF6-4971-A4B7-9E6ABF818C0CQ35932609-B0900707-02EC-4A6E-A1F8-B979C263F4F0Q36187988-75F11B22-777F-4E97-A8DE-5524A91F1BE7Q36200301-AB33DB0E-683D-4C08-AF1A-0E579FC563C8Q36382897-56E4612B-D365-4711-9640-AE255B6014ACQ36424889-F82B538D-DE3D-4496-9502-B617C00BD6CBQ36504123-663E0A0C-07D5-4D28-AE2E-12C5F3C3F498Q36693175-0967821C-BDB2-4EBF-81E7-EA19A5A1D848Q36944749-3A5206BD-4C99-453B-B0D4-3B849F27820AQ37059747-F5FF094A-69A1-4B21-8028-F360C0DF42F1Q37081835-633B6454-12A8-4498-915D-52147D1D87BCQ37101303-3D6BF9EF-964E-4474-A00D-D7110C1E0FAFQ37225371-7A955A0D-AECF-45B9-AB41-9DAB5B4D3A0BQ37328021-D9D0FA8B-A7FD-46B8-A303-29A5C7A432F2Q37396270-89F4E0CB-BE3A-4C67-9E7F-0D1949F49A91Q37689788-6C84B211-CFF3-4754-98B5-EB692B8ED1DEQ37741425-E2494E8C-3F2B-4D2D-8F08-AEF698904247Q38201655-E6D57BAE-B684-4B1D-8AEA-CDEA0CE3D0F9Q38221967-AA4DB1D4-CAC0-466F-986F-731562C8EC72Q38635910-32EB8663-3465-476C-8D7B-DAB848AF1BB8Q38681576-18348A16-448B-4D7D-A3BF-2D0A23005088Q38720232-8A85CF12-F1D4-4A30-85ED-E47978A314C8Q38757103-ECA113A1-3DA0-47C8-987A-E3516537E6FDQ38758038-CF4CE4C9-3673-422C-90CA-5A09B23064B1Q38849399-3F4413AF-C99A-4920-96E1-FB34B733B47BQ38875037-2ECE7DA6-F5CA-45B5-9961-907F582C522C
P2860
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interactions between immunity, ...... pe in breast cancer prognosis.
@en
Interactions between immunity, ...... pe in breast cancer prognosis.
@nl
type
label
Interactions between immunity, ...... pe in breast cancer prognosis.
@en
Interactions between immunity, ...... pe in breast cancer prognosis.
@nl
prefLabel
Interactions between immunity, ...... pe in breast cancer prognosis.
@en
Interactions between immunity, ...... pe in breast cancer prognosis.
@nl
P2093
P2860
P50
P356
P1433
P1476
Interactions between immunity, ...... pe in breast cancer prognosis.
@en
P2093
Christos Sotiriou
James P Vaughn
Jeff W Chou
Jimmy Ruiz
Jonas Bergh
Mark C Willingham
Purnima Dubey
Srikanth Nagalla
Timothy L Lash
P2860
P2888
P356
10.1186/GB-2013-14-4-R34
P577
2013-04-29T00:00:00Z